Drugs /

incagn02390

Back to Drugs List

Overview

NCI Definition [1]:
A fully human Fc-engineered immunoglobulin G1 kappa (IgG1kappa) antibody directed against the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, INCAGN02390 forms a high-affinity interaction with TIM-3 expressed on certain T-cells, thereby preventing the engagement of TIM-3 by its ligands, phosphatidylserine (PtdSer) and galectin-9. This abrogates T-cell inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. Additionally, INCAGN02390 elicits TIM-3 receptor internalization, potentially preventing interactions with other ligands.TIM-3, a transmembrane protein and immune checkpoint receptor expressed on certain lymphocytes, including tumor infiltrating lymphocytes (TILs), is associated with tumor-mediated immune suppression.

Clinical Trials

View Clinical Trials for incagn02390

Incagn02390 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating incagn02390, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open).

Malignant solid tumor is the most common disease being investigated in incagn02390 clinical trials [2].

Drug Details

Synonyms [2]:
incagn-02390, anti-tim-3 monoclonal antibody incagn02390, incagn 02390
Drug Target(s) [2]:
HAVCR2
NCIT ID [1]:
C162625

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.